FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy

International Journal of Oncology

Volumn 39, Issue 1, 2011, Pages 91-100

  Katz, Sharyn I ^c   Zhou, Lanlan ^a,e   Ferrara, Thomas A ^c   Wang, Wenge ^f   Mayes, Patrick A ^g   Smith, Charles D ^d   El Deiry, Wafik S ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b AMERICAN CANCER SOCIETY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^g Mount Vernon Hospital USA   (United States)

Author keywords

FLT; Non small cell lung cancer; p53; PET

Indexed keywords

3' FLUOROTHYMIDINE F 18; CISPLATIN; DOCETAXEL; FLUORODEOXYGLUCOSE F 18; PROTEIN P53; SORAFENIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA DAMAGE; DRUG RESPONSE; FEMALE; HUMAN; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR GROWTH; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZENESULFONATES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DISEASE MODELS, ANIMAL; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MICE; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955995712     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1019     Document Type: Article

References (52)

1. Chiba I, Takahashi T, Nau MM, et al: Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene 5: 1603-1610, 1990.
2. Iggo R, Gatter K, Bartek J, Lane D and Harris AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335: 675-679, 1990. (Pubitemid 20089305)
3. Bircan A, Bircan S, Kapucuoglu N, et al: Maspin, VEGF and p53 expression in small biopsies of primary advanced lung cancer and relationship with clinicopathologic parameters. Pathol Oncol Res 16: 553-561, 2010.
4. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009
5. 18F-fluorothymidine for quantitative cell proliferation imaging in subcutaneous tumor models in mice. J Nucl Med 49: 2057-2066, 2008.
6. 18F]fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin's lymphoma. Vet Radiol Ultrasound 50: 660-668, 2009
7. 18F-FDG PET to measure response to radiotherapy combined with celecoxib in two colorectal xenograft models. Int J Radiat Biol 85: 763-771, 2009.
8. Pantaleo MA, Landuzzi L, Nicoletti G, et al: Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors model. Clin Exp Med 9: 199-205, 2009
9. Graf N, Herrmann K, den Hollander J, et al: Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment. Mol Imaging Biol 10: 349-355, 2008.
10. 18F]fluoro-3′-deoxythymidine (FLT). Mol Imaging Biol 9: 340-347, 2007
11. 18F]FLT. Eur J Nucl Med Mol Imaging 34: 1775-1782, 2007. (Pubitemid 47599048)
12. Chao KS: 3′-deoxy-3′-(18)F-fluorothymidine (FLT) positron emission tomography for early prediction of response to chemoradiotherapy - a clinical application model of esophageal cancer. Semin Oncol 34: S31-S36, 2007
13. 18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 65: 4202-4210, 2005 (Pubitemid 40775658)
14. 18F] fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 63: 3791-3798, 2003. (Pubitemid 36793068)
15. 18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 14: 7423-7429, 2008.
16. 18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer. Oral Oncol 45: e211-215, 2009
17. 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 75: 1098-1104, 2009
18. Ullrich RT, Zander T, Neumaier B, et al: Early detection of erlotinib treatment response in NSCLC by 3′-deoxy-3′-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). PLoS One 3: e3908, 2008.
19. 18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res 13: 3552-3558, 2007 (Pubitemid 46955115)
20. 18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25: 4714-4721, 2007 (Pubitemid 350086472)
21. 18F-FDG: a comparative analysis. J Nucl Med 48: 1945-1950, 2007.
22. 18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34: 1339-1347, 2007 (Pubitemid 47312585)
23. Pio BS, Park CK, Pietras R, et al: Usefulness of 3′-[F-18]fluoro- 3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 8: 36-42, 2006. (Pubitemid 44201576)
24. 18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med 45: 1754-1758, 2004 (Pubitemid 47618487)
25. Brockenbrough JS, Morihara JK, Hawes SE, et al: Thymidine kinase 1 and thymidine Phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation. J Histochem Cytochem 57: 1087-1097, 2009
26. Munch-Petersen B, Cloos L, Jensen HK and Tyrsted G: Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul 35: 69-89, 1995
27. Strawn LM, Kabbinavar F, Schwartz DP, et al: Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts. Clin Cancer Res 6: 2931-2940, 2000. (Pubitemid 30482136)
28. Miknyoczki SJ, Jones-Bolin S, Pritchard S, et al: Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2: 371-382, 2003.
29. Gourdeau H, Leblond L, Hamelin B, et al: Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxyphenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents. Mol Cancer Ther 3: 1375-1384, 2004
30. Zhang J, Wang X, Lin CJ, Couch FJ and Fei P: Altered expression of FANCL confers mitomycin C sensitivity in Calu-6 lung cancer cells. Cancer Biol Ther 5: 1632-1636, 2006.
31. Teicher BA, Chen V, Shih C, et al: Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res 6: 1016-1023, 2000. (Pubitemid 30159362)
32. Davies BR, Logie A, McKay JS, et al: AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/ pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 6: 2209-2219, 2007
33. Hurtubise A and Momparler RL: Evaluation of antineoplastic action of 5-aza-2′-deoxycytidine (Dacogen) and docetaxel (Taxotere) on human breast, lung and prostate carcinoma cell lines. Anticancer Drugs 15: 161-167, 2004 (Pubitemid 38316750)
34. Ricci MS, Kim SH, Ogi K, et al: Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 12: 66-80, 2007 (Pubitemid 47001783)
35. Stegehuis JH, De Wilt LH, De Vries EG, et al: TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives. Drug Resist Updat 13: 2-15, 2010.
36. Voortman J, Resende TP, Abou El Hassan MA, Giaccone G and Kruyt FA: TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther 6: 2103-2112, 2007 (Pubitemid 47052501)
37. Spierings DC, De Vries EG, Timens W, et al: Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 9: 3397-3405, 2003. (Pubitemid 37082735)
38. Blumenschein GR Jr, Gatzemeier U, Fossella F, et al: Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 27: 4274-4280, 2009
39. Blumenschein G Jr: Sorafenib in lung cancer: clinical developments and future directions. J Thorac Oncol 3: S124-S127, 2008.
40. Kim SH, Kim K, Kwagh JG, et al: Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem 279: 40044-40052, 2004 (Pubitemid 39258279)
41. Dumas J, Hatoum-Mokdad H, Sibley RN, et al: Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor. Bioorg Med Chem Lett 12: 1559-1562, 2002. (Pubitemid 34569242)
42. 18F-FDG-microPET or external caliper. BMC Med Imaging 8: 16, 2008.
43. Ten Tije AJ, Verweij J, Loos WJ and Sparreboom A: Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 42: 665-685, 2003. (Pubitemid 36936530)
44. Hu CM and Chang ZF: Mitotic control of dTTP pool: a necessity or coincidence? J Biomed Sci 14: 491-497, 2007
45. Bading JR and Shields AF: Imaging of cell proliferation: status and prospects. J Nucl Med 49 (Suppl. 2): S64-S80, 2008.
46. Farnebo M, Bykov VJ and Wiman KG: The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun 396: 85-89, 2010.
47. Chen YL, Eriksson S and Chang ZF: Regulation and functional contribution of thymidine kinase 1 in repair of DNA damage. J Biol Chem 285: 27327-27335, 2010.
48. Rasey JS, Grierson JR, Wiens LW, Kolb PD and Schwartz JL: Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 43: 1210-1217, 2002. (Pubitemid 34988769)
49. Schwartz JL, Tamura Y, Jordan R, Grierson JR and Krohn KA: Effect of p53 activation on cell growth, thymidine kinase-1 activity, and 3′-deoxy- 3′fluorothymidine uptake. Nucl Med Biol 31: 419-423, 2004 (Pubitemid 38490741)
50. Soussi T and Wiman KG: Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 12: 303-312, 2007 (Pubitemid 47539312)
51. Jin W, Cai L, Niu G and Tao H: Proliferation inhibition effect of docetaxel combined with cisplatin on osteosarcoma cells. Med Oncol 27: 491-494, 2010.
52. 18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 29: 1462-1469, 2002. (Pubitemid 35232048)